Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (2557)	4/23/2008 12:17:08 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3158

>> I would want to see longer term data << Me too, except that I'm excited re. efficacy, and looking forward to a longer trial with drug vacations. >> Note also that the study was performed on top of MTX << Yes, thanks!........ 12 week trial, active disease for at least a year despite ongoing mtx and continuing mtx during trial. (for those who follow this thread but have no biology bkgd., mtx can also lead to neutropenia.... it's likely that mtx and R788 have overlying toxicities.) Re. infections..... not new... study after study with anti-TNFs show an increased frequency of infection. And, as you note, neutrophils can be monitored. Distinct activity in RA is observed with manageable tox at 100 mg for 12 weeks on top of mtx. Looking forward to trials with drug vacations, no mtx, etc. >> study that appears to be superbly carried out << Somebody in Regulatory has a brain. mice versus humans.... ok, thanks! Rick